Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

In a world shaped by biotechnology, why are so few college students exposed to its possibilities early on in their education?

A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

Biotech is growing in North Carolina, and now one Triad college is stepping up to help train the workforce. Guilford Technical Community College is launching a ...

Anbio Biotechnology’s NNNN share price has surged by 5.23%, which has investors questioning if this is right time to sell.

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Professor Emeritus Herb Boyer's discovery of recombinant DNA changed medicine, ushering in a new era in biological treatments ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...